Ampersand, Rapport launches reflect precision medicine trend
Plus: Noema and LENZ raise oversubscribed series B rounds
Precision medicine was the theme of two new company launches announced on Tuesday. Both Boston-based newcos are aiming for a higher degree of precision than past targeted therapies by pairing specific molecular targets or mutations with methods to better direct the therapies to the disease-relevant tissues and cells.
Ampersand Biomedicines Inc., the latest company to emerge from Flagship Pioneering, is using its $50 million of funding to develop a platform for creating modular therapeutics that are localized to specific target tissues, where they are conditionally activated...